2 weeks Ago By ABMN Staff
Arizona State Retirement System lifted its holdings in TG Therapeutics, Inc. ( NASDAQ:TGTX – Free Report ) by 3.9% during the second quarter, according to its most recent Form 13F filing with the SEC.
The firm owned 41,069 shares of the biopharmaceutical company’s stock after purchasing an additional 1,539 shares during the period. Arizona State Retirement System’s holdings in TG Therapeutics were worth $731,000 as of its most recent filing with the SEC. Other institutional investors and hedge funds also recently made changes to their positions in the company.
Vanguard Group Inc. grew its position in shares of TG Therapeutics by 1.5% during the 4th quarter.
Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after buying an additional 199,770 shares during the period. Wellington Management Group LLP increased its position in TG Therapeutics by 1.
4% during the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after buying an additional 43,290 shares during the last quarter. Opaleye Management Inc.
raised its stake in TG Therapeutics by 2.9% in the 1st quarter. Opaleye Management Inc.
now owns 2,280,000 shares of the biopharmaceutical company’s stock valued at $34,679,000 after acquiring an additional 65,000 shares during the period. Hood River Capital Management LLC acquired a new stake in shares of TG Therapeutics during the 1st quarter worth about $22,420,000. Finally, Charles Schwab Investment Management Inc.
boosted its holdings in shares of TG Therapeutics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc.
now owns 1,131,896 shares of the biopharmaceutical company’s stock worth $19,333,000 after acquiring an additional 19,214 shares during the period. Institutional investors own 58.58% of the company’s stock.
Analysts Set New Price Targets A number of research analysts have commented on TGTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a report on Tuesday, August 6th.
B. Riley upped their price target on shares of TG Therapeutics from $29.00 to $34.
00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $18.00 to $20.
00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.83. TG Therapeutics Stock Up 2.
3 % NASDAQ TGTX opened at $23.73 on Monday. The business has a fifty day moving average price of $21.
63 and a two-hundred day moving average price of $18.09. The stock has a market capitalization of $3.
67 billion, a PE ratio of 103.17 and a beta of 2.21.
TG Therapeutics, Inc. has a fifty-two week low of $6.46 and a fifty-two week high of $25.
70. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.
58 and a quick ratio of 2.83. TG Therapeutics ( NASDAQ:TGTX – Get Free Report ) last released its quarterly earnings data on Tuesday, August 6th.
The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.
08. The business had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.
92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.
60%. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year.
During the same period last year, the firm posted ($0.34) earnings per share. Equities analysts expect that TG Therapeutics, Inc.
will post 0.13 earnings per share for the current fiscal year. TG Therapeutics Company Profile ( Free Report ) TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. Featured Stories Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc.
( NASDAQ:TGTX – Free Report ). Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
